[Prevention of postenucleation syndrome: the hydroxylapatite silicone implant. Preliminary experimental studies and initial clinical experiences].
An orbital implant after enucleation compensates for volume deficiency and increases prosthesis motility. In the literature, however, an extrusion rate of orbital implant between 10 and 25% is reported. Since the introduction of hydroxylapatic ceramics (HAC), these numbers have been reduced considerably. The HAC, which is derived from corals, has a rough surface and requires a scleral covering for implantation. The HAC, which is made in the laboratory, can be produced with smoother surfaces, so that a homoplastic covering is no longer mandatory. A composite implant was developed to improve prosthesis motility further. This consists of artificial HAC at its anterior surface to guarantee safe tissue integration; the posterior part of the implant is manufactured from silicon rubber to create a jointlike structure in Tenon's capsule. Integration of the porous HAC in the orbital soft tissues has been tested and confirmed by animal experiments. After 30 full HAC implants and 25 composite implants, only one extrusion occurred. In all other cases, compatibility proved to be excellent; transmission of the motility to the prosthesis was moderate to good. Examinations comparing prosthesis motility and computer tomographically evaluated implant motility enabled the analysis of deficits in motility transmission of the implant for the artificial eye.
Guthoff
R
R
Universitäts-Augenklinik Rostock.
Vick
H P
HP
Schaudig
U
U
D000818:Animals; D017886:Durapatite; D015353:Eye Enucleation; D005133:Eye Movements / Q000502:physiology; D005137:Eye, Artificial; D005549:Foreign-Body Reaction / Q000473:pathology; D006801:Humans; D008422:Materials Testing; D009915:Orbit / Q000473:pathology; D011183:Postoperative Complications / Q000473:pathology / Q000517:prevention & control*; D019736:Prostheses and Implants; D011817:Rabbits; D012828:Silicones
D012828:Silicones; D017886:Durapatite
Zur Prophylaxe des Postenukleationssyndroms: Das Hydroxylapatitsilikon-implantat. Experimentelle Vorarbeiten und erste klinische Erfahrungen.